GHRP-2 Research Evidence
The GHRP-2 evidence base: trials, journals, and what the data does not yet show.
Key Findings at a Glance
• GHRP-2 is generally considered the most potent GHRP for growth hormone stimulation on a per-microgram basis while producing substantially less appetite stimulation than GHRP-6. • Despite frequent claims that GHRP-2 deepens sleep, a placebo-controlled study found evidence against a role for the GHRP axis in human slow-wave sleep, even though deep sleep and the nocturnal GH pulse naturally coincide. • GHRP-2 maintains its GH-releasing effectiveness in elderly subjects, with only modest age-related decline compared to the dramatic reduction in natural GH secretion seen with aging. • GHRP-2 has been formally studied as a diagnostic tool for assessing pituitary GH reserve, giving it a clinical validation path distinct from most research peptides.
Moderate Appetite Effects
GHRP-2 produces significantly less appetite stimulation compared to GHRP-6, typically causing mild hunger increases in approximately 30-40% of research subjects compared to the near-universal appetite effects observed with GHRP-6. This reduced ghrelin-mimetic activity at hypothalamic appetite centers makes GHRP-2 particularly suitable for metabolic research studies where hunger confounds would complicate data interpretation. Research indicates GHRP-2's modest appetite effects result from lower intrinsic activity at the orexigenic signaling pathways downstream of GHSR-1a activation compared to its robust GH-releasing potency. The balanced profile between GH stimulation and appetite modulation positions GHRP-2 as an ideal research tool for body composition studies, muscle protein synthesis research, and investigations where maintaining controlled feeding conditions is essential. Studies comparing GHRP family members consistently rank GHRP-2 between Ipamorelin (minimal appetite effects) and GHRP-6 (strong appetite effects) on the spectrum of hunger induction.
Sleep Research
The relationship between GHRP-2 and sleep is frequently discussed because slow-wave (deep) sleep naturally coincides with the largest nocturnal growth hormone pulse. However, controlled human data do not support the idea that GHRP-2 enhances slow-wave sleep: a placebo-controlled polysomnography study found evidence against a role for the GHRP axis in human slow-wave sleep, despite the temporal correlation between deep sleep and nocturnal GH secretion. Interest remains in clarifying how growth hormone secretagogues interact with sleep architecture—particularly in aging, where both GH secretion and slow-wave sleep decline—but current evidence does not establish GHRP-2 as a sleep-enhancing agent.
Trials and reviews
- Mericq graded-dose GHD trialJCEM1998
8-month graded-dose trial in GH-deficient children · GH secretion restored
- Wu sleep RCT (negative)Am J Physiol1998
placebo-controlled IV GHRP-2 · no effect on slow-wave sleep · N=7
References
- Growth hormone-releasing peptide-2 stimulates GH secretion · Bowers CY · 1998
- Arvat E, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6):885-891. · Arvat E, di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, Camanni F, Ghigo E · 1997
- The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. · Van den Berghe G, Baxter RC, Weekers F et al. · 2002
- Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide ... · 2004
- Mericq V, et al. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. Journal of Clinical Endocrinology & Metabolism. 1998;83(7):2355-2360. · Mericq V, Cassorla F, Salazar T, Avila A, Iñiguez G, Bowers CY, Merriam GR · 1998
- Synergy of L-arginine and GHRP-2 stimulation of growth hormone in men and women: modulation by exercise. · Wideman L, Weltman JY, Patrie JT et al. · 2000
- Berlanga-Acosta J, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clinical Medicine Insights: Cardiology. 2017;11:1179546817694558. · Berlanga-Acosta J, Abreu-Cruz A, Herrera DGB, Mendoza-Marí Y, Rodríguez-Ulloa A, García-Ojalvo A, Falcón-Cama V, Hernández-Bernal F, Beichen Q, Guillén-Nieto G · 2017
- Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children. · Pihoker C, Kearns GL, French D et al. · 1998
- Pralmorelin - an overview | ScienceDirect Topics
- Association between overweight and growth hormone secretion in patients with non-functioning pituitary tumors. · Seki Y, Ichihara A · 2022
- Pralmorelin | C45H55N9O6 | CID 6918245 - PubChem - NIH
- Laferrere B, et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. Journal of Clinical Endocrinology & Metabolism. 2005;90(2):611-614. · Laferrère B, Abraham C, Russell CD, Bowers CY · 2005